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Background: The demand for uterus-sparing treatments is increasing as more women postpone childbirth to their
30–40s, when fibroids are more symptomatic. With an increasing choice of treatment options and changing
care-provider profiles, now is an opportune time to survey current practices and opinions. Using a 25-stem
questionnaire, a web-based survey was used to capture the practices and opinions of UK consultant gynecologists
on the treatment of symptomatic fibroids, including the types of procedure most frequently used, methods used to
reduce blood loss, and awareness and acceptability of treatment options, and to assess the impact of gender and
experience of the treating gynecologist.
Results: The response rate was 22%. Laparascopic myomectomy is used least frequently, with 80% of the
respondents using GnRHa preoperatively to minimize blood loss and correct anemia, while vasopressin is most
frequently used to reduce intraoperative blood loss. Female consultants operate significantly less frequently than
males. Those with more than 10 years consultant experience are more likely to perform an open myomectomy
compared to those with less than 10 years experience.
Conclusions: Compared to a similar survey performed 10 years ago, surgical methods remain to be the most
common treatments, but use of less invasive treatments such as UAE has increased. Consultants’ attitudes appear to
be responding to the patient demand for less radical treatments. However, it is yet to be seen if the changing
consultant demographics will keep up with this demand. The low response rate warrants cautious interpretation of
the results, but they provide an interesting snapshot of current views and practices.
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Fibroids are the most common tumor in women of repro-
ductive age [1, 2]. Recent years have seen a demographic
shift in childbirth trends, with many women delaying
starting their families until they reach their third or fourth
decade [3, 4]. This is the age when fibroids are more
prevalent and symptomatic [5, 6]. The old adage “children
then fibroids and then hysterectomy” therefore no longer
applies to many a modern woman, and there is likely to
be an increasing demand for fertility-preserving treat-
ments for symptomatic uterine fibroids.* Correspondence: imanyond@gmail.com; imanyond@sgul.ac.uk
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the Creative Commons license, and indicate ifThe repertoire of uterus-preserving treatments for symp-
tomatic fibroids has increased in recent years. Just over
20 years ago, the use of uterine artery embolization (UAE)
was first reported [7]. The National Institute for Health and
Clinical Excellence (NICE) has reviewed its efficacy and
recommends UAE as an alternative treatment to hysterec-
tomy and myomectomy [8]. Magnetic resonance (MR)-
guided focused ultrasound (MRgFUS) [9] is another new
technique, but its adoption has been slow, partly due to the
high infrastructure costs of setting up such a service, and
because of its limitations in treating large and/or numerous
fibroids [10, 11]. Pharmaceutical agents continue to be de-
veloped. While it was originally introduced as a pre-
myomectomy treatment [12], ulipristal acetate has recently
acquired a license for use as a stand-alone treatment for
symptomatic fibroids [13] and is regarded by many as theis distributed under the terms of the Creative Commons Attribution 4.0
rg/licenses/by/4.0/), which permits unrestricted use, distribution, and
e appropriate credit to the original author(s) and the source, provide a link to
changes were made.
Table 1 How the respondents defined themselves
% Total number of responses (N)
Generalist 39 117
Minimal access surgeon 15 44
Urogynecologist 8 25
Reproductive medicine specialist 8 25
Gynecological oncologist 5 15
Non subspecialist obstetrician 2 7
Non subspecialist gynecologist 6 19
Missing response 12 36
Total 100 299
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emergence of these new and exciting treatments for man-
aging symptomatic uterine fibroids, in reality, when the
uterus is to be preserved, myomectomy, especially the open
abdominal approach, remains the treatment of choice of
many gynecologists.
Surveys can be a useful tool in the evaluation of health-
care, whether by the recipients of healthcare or the health-
care professionals themselves. Historically, surveys were
predominantly paper based, but the advent of the Internet
and the development of dedicated software such as Sur-
veyMonkey have made surveys much more efficient and
powerful tools. With the new treatment modalities now
embedding, and the changing demographics of both the
profile of gynecological consultants and the population
they serve, we considered it an opportune time to survey
the views and practices of current UK consultant gynecol-
ogists on uterus-sparing techniques. We conducted an on-
line survey and present and compare our findings to a
similar paper-based survey conducted 10 years ago [15].
Methods
Using a web-based survey system (SurveyMonkey, Inc.) a
25-item questionnaire was designed that included ques-
tions on the respondents’ gender, current place of work
(i.e., district general hospital or tertiary center), how long
they had been in a consultant role, and current clinical in-
terests and subspecialty. The questionnaire further sought
the respondents views and practices on the three types of
myomectomy (open, laparoscopic, and hysteroscopic) and
methods used to reduce blood loss both pre- and perio-
peratively. Additional questions were enquired about the
respondents’ access to, and use of, cell salvage, and their
views on UAE and ulipristal acetate (UPA). To refine and
reduce ambiguity, the questionnaire was piloted among
local gynecology consultants before invitations to partici-
pate were sent out nationally. A copy of the final version
of the questionnaire is included in the Additional file 1.
The questionnaires were completed anonymously. The
survey was active between November 2014 and April 2015.
To maximize the response rate, the survey was advertised
in the Royal College of Obstetricians and Gynecologists
(RCOG) monthly electronic newsletter, the Scanner, which
is e-mailed to all RCOG members. Two months after, the
survey opened an invitation to participate and the link to
the survey was also e-mailed to members of the British So-
ciety for Gynecological Endoscopy (BSGE).
As the study did not involve patients or their data,
ethical approval was not required.
Statistical analysis was performed using SPSS software
(IBM SPSS Statistics V22, Chicago, IL). The results are
expressed in percentages (%) and absolute values (n). A
p value equal to or less than 0.05 was considered
significant.Results
Response rate
Of the 1375 consultants invited to participate in the sur-
vey, 299 responded, a response rate of 22%.1 Among the
respondents, a minority did not answer every question
applicable to them. Therefore, for some questions dis-
cussed below, the total numbers are smaller than 299.
Demographics
Thirty-six percent (n = 108) of respondents were female
and 51% (n = 152) were male while 13% (n = 39) did not to
disclose their gender. This correlates well with the actual
gender distribution of current consultants in practice and
gives some credence that the responses in our survey are
representative of the workforce as a whole: as of 2013, 47%
of the consultant workforce in the UK was female and 53%
male [16]. Just under half of the respondents (48%, n = 143)
were based in district general hospitals, 36% (n = 106) were
working in university teaching hospitals, 4% (n = 11)
worked exclusively in the private sector and 12% (n = 36)
did not indicate the sector in which they worked. Since
doctors enter into the specialty at varying ages, we did not
record our respondents’ age, but rather how many years
they have been at the consultant grade. We found that male
respondents had practiced for more years than their female
colleagues. While 60% of female consultants had less than
10 years experience, 72% of males had 10 years or more ex-
perience. This is also in line with the experience status of
the current consultant cohort [16].
Thirty-nine percent (n = 117) described themselves as
generalists in Obstetrics and Gynecology, and 15% (n =
44) responded that they were sub-specialists in Minimal
Access Surgery (MAS) (Table 1.).
Performance of myomectomy for symptomatic fibroids
With regard to performing myomectomy, 81% (n = 243)
stated that they performed some type of myomectomy.
Open myomectomy was the procedure performed by the
vast majority (74%, n = 221). Hysteroscopic procedures
were performed by 56% (n = 166), and 32% of the
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myomectomy, while 29% (n = 86) of our respondents re-
ported that they perform all three types of myomectomy.
Three fifths (46%, n = 138) of respondents reported
that the size of the uterus would not influence their de-
cision whether or not to perform open myomectomy.
There is no limit on the number of fibroids removed
laparoscopically by 18% (n = 54) and hysteroscopically by
31% (n = 93). Only 43% (n = 127) aim to remove all fi-
broids during an open myomectomy.
Male consultants are significantly more likely to perform
a myomectomy compared to their female counterparts
(90%, n = 137 males versus 69%, n = 74 females). Logistic
regression modeling confirmed that this association was
significant. Binary logistic regression modeling also showed
that the experience and subspecialty/special interests of the
consultants had a significant impact on their choice of per-
forming or not performing myomectomy (Table 2).
Consultants with more experience are significantly
more likely to perform myomectomy than their col-
leagues with less than 10 years’ experience at consultant
level (OR = 0.312, p = 0.012). Similarly, male consultants
are also significantly more likely to operate compared to
their female counterparts (OR = 0.232, p = 0.01). Perhaps
unsurprisingly, respondents who described themselves as
fetal medicine specialists operate significantly less than
those in other subspecialties. The majority of respon-
dents (89%, n = 194) agreed that complex fibroid surgery
should only be performed by experienced gynecologists
who frequently perform this operation.
Attitudes towards myomectomy and women’s wishes
Fifty-four percent (n = 160) of our respondents said that
they would offer a myomectomy to a woman whose
family is complete, but who simply wishes to retain her
uterus because she feels a more “complete woman”.Table 2 Key drivers for not performing myomectomy
Variables
Female (compared to male)
Experience 0–9 years (compared to 10 years+)
Obstetrics and Gynecology (compared to Generalist)
Obstetrics (non-subspecialist) only
Gynecology (non-subspecialist) only
Subspecialist/special interest in Gynecological Oncology
Subspecialist/special interest in Urogynecology
Subspecialist/special interest in Reproductive Medicine
Subspecialist/special interest in Fetal Maternal Medicine
Subspecialist/special interest in Minimal Access Surgery
Constant
Coefficients significantly different from zero at the 0.05 level or better are shown in
SE Standard error, Sig Significance, OR odds ratioSimilarly, 175 respondents (59%) stated that they would
perform a repeat myomectomy on a woman who wished
to retain her fertility.
Preventing and minimizing blood loss, the use of GnRH
analogues (GnRHa), uterine artery embolization (UAE),
and ulipristal acetate (UPA)
Although used in women undergoing all three types of
myomectomy, the responses to our survey show that
86% (n = 257) of consultants use GnRHa prior to open
myomectomy. Twenty-one percent (n = 62) used GnRHa
prior to laparoscopic myomectomy while 44% (n = 131)
use GnRHa prior to hysteroscopic myomectomy. The in-
dications stated for GnRHa use were to correct anemia
prior to surgery (50%, n = 148) and to reduce fibroid size
to allow a lower transverse incision rather than a midline
one (51%, n = 151). Interestingly, 41% (n = 122) stated
that they use them despite knowing that GnRHa destroy
tissue planes, thus rendering surgery more difficult.
Thirty percent (n = 91) of our respondents reported
that they cross match blood for every open myomec-
tomy they perform. Vasopressin was used by 29% (n =
86), while tourniquets/clamps were used by 20% (n = 57)
to minimize blood loss during open myomectomy. Fif-
teen percent reported that they do not use any specific
technique, and 44% (n = 132) have access to a cell sal-
vage facility (Table 3).
Sixty-two percent (n = 184) of the respondents have
access to UAE for the treatment of symptomatic uterine
fibroids. When asked whether they would offer UAE to
women wishing to conceive, 43% (n = 127) replied that
they would. Forty-nine percent (n = 146) have read the
joint guidelines published by The Royal College of Ob-
stetrics and Gynecologists/Royal College of Radiologists
[17] on the use of UAE for the treatment of uterine
fibroids.SE Sig. OR
.459 .001 .232
.464 .012 .312
.001
14,129.622 .999 .000
.672 .078 .306
.861 .496 .556
.645 .003 .146
.835 .975 1.027
.842 .000 .035
1.066 .108 5.554
.533 .000 32.073
italics
Table 3 Methods used to reduce intraoperative blood loss
Methods used to minimize blood loss N %
Vasopressin 86 29
Tourniquets/clamps 57 19
Tranexamic acid 37 12
Oxytocin 3 1.0
Misoprostol 1 0.3
No method used 43 14
Missing 72 24
Total 299 100
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aware of UPA, and 32% (n = 96) had used it pre-
myomectomy. On the other hand, 29% (n = 87) respon-
dents had never used UPA, while a mere 10% (n = 29) had
used UPA for treating conditions other than symptomatic
uterine fibroids, such as emergency contraception.
Discussion
With a response rate of 22%, we are acutely aware of the
need to interpret our findings with caution. However,
the correlation between the results obtained in our sur-
vey with published gender breakdown of current consul-
tants suggests that our respondents reflect the make up
of consultants in the UK [16], and therefore, our find-
ings provide a useful snapshot of current views and
practices in the management of fibroids.
Although surveys are an important tool in the evalu-
ation of health services, it would appear that response
rates to most surveys have been declining over the years.
Historically, surveys were conducted via the post, with
apparently good responses. Thus, a postal survey on the
same issue of myomectomy conducted by Taylor et al.
[15] 10 years ago yielded a response rate of 54%. One
would have assumed that the advent of the internet, with
access to online surveys and the advantages of instant
survey delivery, real-time data collection, ease of access
for respondents, and increased respondent anonymity
would increase the response rates for surveys. This does
not appear to be the case, and it is reported that re-
sponse rates differ among various specialties [18]. The
ease of use of e-surveys may in fact be a factor contrib-
uting to the decline in response rates, as people are
bombarded with a multitude of surveys, and it is so easy
to delete the e-mail without even opening it. In a meta-
analysis of 68 web-based health surveys, the mean
response rate reported in 49 studies was 39.6% [19]. How-
ever, our own recent experience of a 28% response rate
from a postal survey [20] would suggest that there is in-
deed a general decline in response rates, and this is mir-
rored in the experience of other colleagues (Sultan et al.,
personal communication). Thus, many factors probablycontribute to the declining response rates, and it is un-
likely that this trend can be improved significantly.
Despite the emergence of minimally invasive techniques,
including UAE, and the pharmacological agent UPA, our
work suggests that surgery is still the most common form
of fibroid treatment offered in the UK, a finding supported
by work published by the Health and Social Care Informa-
tion Centre, Hospital Episode Statistics (HES) [21].
From their postal survey published 10 years ago,
Taylor et al. [15] reported that 64% of their respondents
performed at least one open myomectomy per year; with
around half (51%) performing between one and five pro-
cedures annually. Our own survey suggests that the
number of surgeons reporting that they performed be-
tween one and ten myomectomies per year has in-
creased to 62%. Similarly, the rate of laparoscopic
myomectomy has risen from 11 to 32%. Whether this is
a reflection of the increased demand for uterine sparing
procedures or has resulted from surgeons having a
higher caseload or both remains to be answered.
The use of pre-myomectomy GnRHa use has not chan-
ged in the intervening 10 years: Taylor et al. [15] reported
that 85% of their respondents use GnRHa pre-
myomectomy, and our own survey yielded a similar result
of 86%. Interestingly, 41% of our respondents stated that
GnRHa destroy tissue planes and thus render the surgery
more difficult. The Cochrane review on the preoperative
use of GnRH comments that “fibroid capsule will become
less evident and may be missed, tumours will not “shell
out” cleanly and the excision may be more difficult” [22].
The literature also reports that the use of GnRHa is not
cost-effective [23], delays surgery, and is associated with sig-
nificant side effects and bone demineralization, and there
are much cheaper alternatives such as progestogens to pre-
vent menstruation while correcting anemia [24]. Further
evidence is emerging regarding the preoperative use of
UPA which could be a better alternative to GnRH: a recent
study from Canada investigated the surgical experience of
patients that underwent laparoscopic or robotic myomec-
tomy following UPA treatment and found no difference
compared to non-treated patients [25]. On a similar note,
Sancho et al. described a case series where no difficulty was
observed during hysteroscopic fibroid resection following
UPA treatment [26].
Only one in five of the respondents to our survey re-
ported that they used tourniquets or clamps. This is des-
pite reports that the application of tourniquets is more
effective than GnRHa in minimizing blood loss [27]. Our
survey found that perioperatively, 29% (n = 86) of gynecol-
ogists use vasopressin to minimize blood loss. This rela-
tively low rate may reflect concerns that have been raised
recently concerning the safety of vasopressin [28].
Taylor et al. [15] reported that only 28% of their re-
spondents were prepared to perform a myomectomy on
Sirkeci et al. Gynecological Surgery  (2017) 14:11 Page 5 of 6a 50-year-old woman, presumably on the assumption that
they no longer needed their uterus. While we did not ask
this exact same question, 54% of respondents to our survey
replied that they would perform a myomectomy on a
woman who has completed her family, and 59% would per-
form a repeat myomectomy. These responses may reflect
an increasing awareness and acceptance of women’s auton-
omy, as well as being driven by the changing demography
of many women delaying childbirth until later in life.
Transformed attitudes may also be reflected in the in-
creased awareness and acceptance of UAE seen in our
survey. Taylor et al. [15] reported that only around half
of their respondents had ready access to UAE. Our work
suggests that this figure has risen to 62%. In the past, it
was a common opinion that UAE should not be offered
to women wishing to conceive, and this is reflected in
26% of the participants in Taylor et al.’s study who
agreed that they would offer UAE to such women. With
ever increasing reports of women having successful
pregnancies following UAE, guidance is no longer quite
so didactic, and in our survey, 43% of all our respon-
dents would offer UAE to women planning conception.
It is interesting to note that the advent of UAE and other
uterus-sparing treatments have not reduced the number
of myomectomies being carried out, perhaps another re-
flection that women have been demanding more uterine
saving procedures compared to a decade ago.
According to the Centre for Workforce Intelligence’s
latest report [16], the number of women in the Obstet-
rics and Gynecology workforce has increased more than
fourfold, from around 200 in 1998 to over 893 in 2013.
In the last few years, over four fifths (81%) of specialist
trainees in Obstetrics and Gynecology are female. In our
survey, three fifths (59%) of respondents were male. Of
the male respondents, 90% reported that they performed
some type of myomectomy, while the figure is signifi-
cantly lower among females. The percentage of male
consultants performing myomectomy with 10 years or
more experience is 90% whereas the corresponding fig-
ure for females is 74% (p = 0.003). Among those with less
than 10 years experience, the contrast is even starker as
only 64% of females perform myomectomy compared to
91% of male consultants (p = 0.016). This raises an im-
portant question: is the lower surgery rate seen in
women in our survey a result of their relative inexperi-
ence, or does this signify a paradigm shift away from
surgery that female gynecologists deem unnecessary and
towards the use of other primary treatments for symp-
tomatic uterine fibroids? If the former, then our survey
raises an important issue, which has major implications
for training and workforce planning, namely, who will
perform the myomectomies of tomorrow?
If we are to offer our patients the best outcomes, then any
treatment of significant complexity should be delivered by ahighly trained individual who administers that treatment on
a frequent basis. Our specialty has seen a move away from
“generalists” and towards dedicated sub-specialists such as
those treating gynecological cancers, women with urinary
disorders, and high-risk pregnancies. Fibroid surgery can be
challenging, and it is informative that 89% of all our respon-
dents agreed that only experienced gynecologists who per-
form these operations frequently should undertake complex
fibroid surgery. Increasing rates of both open and minimally
access surgery rates support our views that there is a de-
mand for a subspecialist competent in all forms of myomec-
tomy. As fibroids present in a wide range of sizes and
locations with variety of symptoms, and patients may wish
to have a selection of treatments; we believe that there sim-
ply is no single ideal treatment. Case-by-case assessment of
each individual patient is therefore necessary to optimize
the treatment where the role of experienced benign
gynecological surgeon is indisputable.
Conclusions
The changing demography of childbirth, with women in-
creasingly postponing pregnancy to an age when fibroids
are more numerous and symptomatic, poses a variety of
challenges. There is a need to research and optimize the
treatment options available, a cadre of highly skilled sur-
geons will be required, and this has major implications for
the training of gynecologists, and new treatments must be
sought that enhance fertility potential and symptom relief
with minimal risk to the woman. Surveys such as the one
presented here provide crucial snapshots of current prac-
tices and views and hopefully help to shape those practices
and future directions.
Endnote
1There were 2225 consultants employed in 154 NHS
units as of 2013. https://www.rcog.org.uk/globalassets/
documents/careers-and-training/census-workforce-plan-
ning/census-report-2013.pdf.
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